Peter Lichtlen
Director/Board Member at LYSOGENE
Peter Lichtlen active positions
Companies | Position | Start | End |
---|---|---|---|
LYSOGENE | Director/Board Member | 2018-03-31 | - |
Independent Dir/Board Member | 2018-03-31 | - | |
Swiss Association of Pharmaceutical Professionals, Inc. | Corporate Officer/Principal | - | - |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Director/Board Member | 2010-12-31 | - |
Chief Tech/Sci/R&D Officer | 2010-12-31 | - | |
Founder | 2010-12-31 | - | |
FMH Swiss Medical Association
FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland. | Corporate Officer/Principal | - | - |
Numab Innovation AG
Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Numab Innovation AG develops multi-specific bio-therapeutics for chronic inflammation and cancer. The private company is based in Wädenswil, Switzerland. | Director/Board Member | - | - |
Career history of Peter Lichtlen
Former positions of Peter Lichtlen
Companies | Position | Start | End |
---|---|---|---|
Sucampo GmbH
Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The private company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. | Corporate Officer/Principal | 2011-07-13 | 2018-01-31 |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | 2003-12-31 | 2008-12-31 |
Sucampo Acquisitions GmbH
Sucampo Acquisitions GmbH Financial ConglomeratesFinance Part of Mallinckrodt Plc, Sucampo Acquisitions GmbH is a Swiss company that provides investment services. The private company is based in Zug, Switzerland. | Director/Board Member | - | - |
SUCAMPO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2014-06-30 | - |
Training of Peter Lichtlen
University of Zurich | Doctorate Degree |
Statistics
International
Switzerland | 9 |
United States | 2 |
France | 2 |
Operational
Corporate Officer/Principal | 4 |
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoral
Commercial Services | 6 |
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
LYSOGENE | Commercial Services |
Private companies | 8 |
---|---|
FMH Swiss Medical Association
FMH Swiss Medical Association Miscellaneous Commercial ServicesCommercial Services FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland. | Commercial Services |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Sucampo GmbH
Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The private company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. | Health Technology |
Swiss Association of Pharmaceutical Professionals, Inc. | |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
Sucampo Acquisitions GmbH
Sucampo Acquisitions GmbH Financial ConglomeratesFinance Part of Mallinckrodt Plc, Sucampo Acquisitions GmbH is a Swiss company that provides investment services. The private company is based in Zug, Switzerland. | Finance |
Numab Innovation AG
Numab Innovation AG Miscellaneous Commercial ServicesCommercial Services Numab Innovation AG develops multi-specific bio-therapeutics for chronic inflammation and cancer. The private company is based in Wädenswil, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- Peter Lichtlen
- Experience